NewsBenzingaAbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease Benzinga 2026.10.23 19:36 (GMT+0) Open on Benzinga Other news LDP: The Family Favorite But Not Enough (NYSE:LDP) Betterware: Tupperware Looks Better, But Jafra Looks Worse (NYSE:BWMX) Palo Alto CEO Nikesh Arora Warns Companies to Assume They Will Get ‘Breached’ and Fix Their ‘Technology Debt’ as AI Uncovers Critical Software Flaws Tower Semiconductor: The Silicon Photonics Opportunity Is Taking Shape (NASDAQ:TSEM) Enovis Screens Cheap, But There Is A Continued M&A Overhang (NYSE:ENOV) Coeur Mining: The Cost Trick Every Silver Investor Should Understand (NYSE:CDE)
Palo Alto CEO Nikesh Arora Warns Companies to Assume They Will Get ‘Breached’ and Fix Their ‘Technology Debt’ as AI Uncovers Critical Software Flaws
